MedTrace Logo

Safety and Efficacy of PG101 for Dry Eye Syndrome

NCT02078661 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2014-03-05

No results posted yet for this study

Summary

To evaluate the safety and efficacy of 0.25% PG101 and 1.0% PG101 topical gel suspension compared to placebo when administered two times daily for 14 days in subjects diagnosed with dry eye syndrome

Conditions

  • Dry Eye Syndrome

Interventions

DRUG

PG101

A topical gel containing either 1% or 0.25% PG101 active.

Sponsors & Collaborators

  • ORA, Inc.

    collaborator INDUSTRY

  • Rhodes Pharmaceuticals, L.P.

    lead INDUSTRY

Principal Investigators

  • Gail Torkildsen, M.D. · Andover Eye

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02078661 on ClinicalTrials.gov